Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury
Abstract Background FTY720 (fingolimod, Gilenya™) is an oral, blood-brain barrier (BBB)-passing drug approved as immunomodulatory treatment for relapsing-remitting form of the multiple sclerosis (MS). In addition, FTY720 exerts several effects in the central nervous system (CNS), ranging from neurop...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-07-01
|
Series: | Journal of Neuroinflammation |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12974-017-0922-6 |